BOULDER, CO--(Marketwired - August 27, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that it is working with the US Department of Commerce's Export Assistance Center In Denver to increase awareness of how the cutting edge Virus Counter system can be used to dramatically accelerate the creation of life-saving products.
According to Paul Bergman, Director of the US Export Assistance Center, "We understand the importance of enabling a rapid response to emerging global pathogens, and are more than happy to support innovative US companies, like Virocyt to get their technology to the regions of the World where it will have the greatest impact. East Asia is playing a growing role in the development and production of vaccines to prevent sickness and death worldwide." As a part of the collaboration, events are being held at the United States' embassies in Beijing, China and Seoul, South Korea at which members of the vaccine community in these countries -- including industry, academic and government groups -- will gather to hear how the US Food and Drug Administration (FDA) is using the Virus Counter instrument to quickly characterize both seasonal and pandemic influenza viruses.
"We are delighted that Dr. Ewan Plant from the Center for Biologics Evaluation and Research (CBER) at the FDA will be discussing his research in this important field," said Robert Kline, President and CEO of ViroCyt. "The Virus Counter has been implemented by leading companies, regulatory agencies and research institutes around the world. Much of this has been driven by the emphasis placed by major stakeholders -- such as the FDA and the Biomedical Advanced Research and Development Authority (BARDA) -- on streamlining the manufacture of vaccines. These factors have led to a sense of urgency to identify and adopt innovative approaches such as the Virus Counter."
Said Mitch Larsen, Counselor for Commercial Affairs for the US Embassy in South Korea, "The Single Company Promotion is designed to introduce new-to-market US companies or raise the market profile of US firms already present in the Korean market. We worked closely with ViroCyt to create unique synergies, meeting and communicating with core client candidates in Korea for the company's product launch. Commercial Services Korea and ViroCyt were successful in organizing and inviting important clients to a special technical seminar, which will take place on September 3, 2014."
ViroCyt, LLC was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at http://www.virocyt.com.